reSee.it Video Transcript AI Summary
A recent report describes a cyberattack and censorship surrounding a peer‑reviewed study that examines cancer diagnoses in relation to COVID vaccination. The study appeared in Oncotarget on January 3 and was authored by cancer researchers from Tufts University and Brown University. It analyzed 69 previously published case reports from around the world, identifying 333 instances where cancer was newly diagnosed or rapidly worsened within a few weeks after vaccination.
The Daily Mail reported that the journal hosting the study was hit by a cyberattack that took the site offline, and that the attack helped propel the paper into broader public attention. The piece notes that the cyberattack was described to have disrupted Oncotarget’s online operations and that the FBI was informed of the incident, though the FBI reportedly would not confirm or deny whether it is investigating the attack.
Among the paper’s authors is Dr. Wafiq Eldiri, who faced ongoing public backlash and personal attacks, including labels such as "scientifically illiterate," "pathetic," and racial insults, as part of a smear campaign tied to the study. Eldiri publicly described the personal attacks he has endured for pursuing the work and stated that he believes it should not be acceptable to attack a physician and biomedical researcher for presenting published literature on COVID infection, COVID vaccines, and cancer.
In a striking twist, two days after the paper’s publication, Pfizer reportedly reached out to recruit Eldiri, praising his expertise in oncologic sciences and offering senior positions. Eldiri released the message publicly and rejected the offer, noting the irony of receiving a Pfizer recruiter message on January 5, 2026.
Eldiri has been vocal about the need for thorough investigations into vaccine safety signals, including potential DNA integration, immune suppression, and cancer risks that could, if substantiated, prompt reconsideration or revocation of emergency use approvals. He suggested that the FDA should work toward revoking or restricting COVID mRNA vaccine approvals if there is insufficient evidence of safety and manufacturing cleanliness, and that evidence should undergo high standards of scrutiny given concerns about assays and reporting of adverse events.
The discussion references other figures and voices in the debate, including Dr. Mary Talley Boden’s assertion that “now we know why the shots are still on the market,” and Dr. Robert Malone’s commentary that Marty Makri could, but will not, remove the shots from the market. The conversation connects these events to broader political and regulatory dynamics, including calls for accountability and for reevaluating emergency approvals in light of emerging data. The piece also touches on fears about future governance of digital identity and related policy implications.